Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Infante on the Next Step in Melanoma Research

June 23rd 2011

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Hoos on a Possible Successor Drug to Ipilimumab

June 22nd 2011

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Vismodegib Trial Yields Benefits in BCC patients

June 20th 2011

Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Wolchok on Patients That Had to Stop Treatment Early

June 20th 2011

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Wolchok Explains the Future of Ipilimumab

June 17th 2011

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Wolchok Describes Candidates for Ipilimumab

June 16th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Chapman on Vemurafenib Combination Therapies

June 16th 2011

Dr. Chapman from Memorial Sloan-Kettering Cancer Center on Vemurafenib Combination Therapies

Dr. Hoos Discusses Key Points of the Ipilimumab Trial

June 15th 2011

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Dr. Chapman Describes Recent Melanoma Advances

June 15th 2011

Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances

Dr. Chapman Describes the Vemurafenib Clinical Trial

June 10th 2011

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Infante on the Future of BRAF Inhibitors in Melanoma

June 8th 2011

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Two Studies Herald New Era in Melanoma Therapy

June 6th 2011

New treatment approaches that improve overall survival for patients with late-stage melanoma spotlighted

Dr. Wolchok Describes the Immunotherapy Ipilimumab

June 6th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

MEK and BRAF Therapy Combo Promising for Advanced Melanoma

June 5th 2011

The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma

Dr. Hoos on the Patients That Respond to Ipilimumab

June 5th 2011

Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab

Dr. Chapman Describes the Side Effects of Vemurafenib

June 5th 2011

Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib

Tim Turnham Discusses Melanoma Treatment Advances

June 4th 2011

Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances